title: Cell recruitment and antigen trafficking in afferent lymph after injection of antigen and poly(I:C) containing liposomes, in aqueous or oil-based formulations.
abstract: After vaccination, innate cell populations transport antigen from the tissue, via the afferent lymphatic vessels, into the local lymph node where they provide critical signals for the generation of an adaptive immune response. The present study uses a unique lymphatic cannulation model to examine, in real time, changes in afferent lymph after injection of a liposome-based delivery system, incorporating diptheria toxoid (DT) and the innate stimulator, poly(I:C). There was a dramatic but temporal recruitment of innate cell populations over time, with neutrophils and monocytes peaking at 6h and 28h post vaccination respectively. The number of dendritic cells (DC) did not increase over the 198h time period, while lymphocytes were slightly elevated at the latest times, indicating the start of an adaptive response. Monocytes and neutrophils were the predominant cell types transporting antigen at the early time points while DC were the most dominant antigen-carrying cells after 78h, predominantly the Sirp-α(high) DC subtype. Resuspending liposomes in oil instead of aqueous solutions has recently been shown to dramatically increase the level and persistence of an immune response and forms the basis of the novel adjuvant formulations, Vaccimax© and Depovax©. In the present study, formulation of the DT and poly(I:C) containing liposomes in an oil carrier dramatically reduced antigen transport to the draining lymph nodes. Examination of the injection site revealed the creation of an ectopic lymphoid tissue with prominent antigen foci and organized lymphoid cells, providing a possible mechanism for the persistence of an immune response in liposome-in-oil adjuvant formulation. Together, the present studies demonstrate the real-time innate in vivo response to vaccination of two novel liposome-based adjuvant systems and the dramatic effect of different carrier formulations.
authors.affiliation: Biotechnology Research Laboratories, School of Biomedical Sciences, Monash University, Vic 3800, Australia. michael.deveer@monash.edu
authors.forename: Michael
authors.initials: M
authors.lastname: de Veer
authors.forename: Melanie
authors.initials: M
authors.lastname: Neeland
authors.forename: Melissa
authors.initials: M
authors.lastname: Burke
authors.forename: Jill
authors.initials: J
authors.lastname: Pleasance
authors.forename: Jackie
authors.initials: J
authors.lastname: Nathanielsz
authors.forename: Martin
authors.initials: M
authors.lastname: Elhay
authors.forename: Els
authors.initials: E
authors.lastname: Meeusen
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D003713:Dendritic Cells / Q000276:immunology; D004168:Diphtheria Toxoid / Q000008:administration & dosage / Q000276:immunology*; D004655:Emulsions / Q000008:administration & dosage; D007279:Injections, Subcutaneous; D007962:Leukocytes / Q000276:immunology; D008081:Liposomes / Q000008:administration & dosage*; D008196:Lymph / Q000166:cytology*; D009821:Oils / Q000008:administration & dosage*; D011070:Poly I-C / Q000008:administration & dosage*; D013997:Time Factors
chemical_list: D000276:Adjuvants, Immunologic; D004168:Diphtheria Toxoid; D004655:Emulsions; D008081:Liposomes; D009821:Oils; D011070:Poly I-C